KTTA: Pasithea Therapeutics Corp. Stock

by  •  • Comments Off on KTTA: Pasithea Therapeutics Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.53
Enterprise Value ($M) -7.83
Book Value ($M) 17.81
Book Value / Share 14.07
Price / Book 0.09
NCAV ($M) 8.95
NCAV / Share 7.07
Price / NCAV 0.17

Profitability (mra)
Return on Invested Capital (ROIC) -0.89
Return on Assets (ROA) -0.60
Return on Equity (ROE) -0.67

Liquidity (mrq)
Quick Ratio 14.81
Current Ratio 14.81

Balance Sheet (mrq) ($M)
Current Assets 9.78
Assets 18.64
Liabilities 0.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
4 days ago 13D/A Steinman Lawrence 3.10 -94.68
02-14 13G/A Armistice Capital, Llc 9.99 15.45

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 12,535 45,265 27.69
2025-03-06 739 14,040 5.26
2025-03-05 80,173 213,143 37.61
2025-03-04 13,501 53,803 25.09

(click for more detail)

Similar Companies
KALA – KALA BIO, Inc. KPRX – Kiora Pharmaceuticals, Inc.
KRRO – Korro Bio, Inc. KZR – Kezar Life Sciences, Inc.
LEXX – Lexaria Bioscience Corp.


Financial data and stock pages provided by
Fintel.io